Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and Age
Authors:
Open Access
- 3 September 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (9) , e2433145
Abstract
Hematopoietic cell transplantation (HCT) is an important treatment modality for hematologic cancers. Because of its medical complexity and high cost, disparities in utilization are well known.1-3 The Center for International Blood and Marrow Transplant Research (CIBMTR) is a national resource to assess HCT volume, but a denominator of patients with transplant-eligible diseases is required to examine utilization. Prior studies estimated the number of eligible cases by applying incidence rates from Surveillance Epidemiology and End Results (SEER) data to US census data to derive the denominator,2-4 with CIBMTR data providing the numerator of HCT volume.3-5 Alternatively, SEER Medicare data have been used to derive both the numerator and denominator, but this limits the study population to Medicare beneficiaries only.6A prior large CIBMTR study demonstrated significant increases in both volume and survival,1,2,5,7 but did not assess the impact of race, ethnicity, or age, nor did it determine if increases in volume or survival were equitable across these vulnerable subgroups.Keywords
This publication has 18 references indexed in Scilit:
- Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous LeukemiaTransplantation and Cellular Therapy, 2022
- Molecular International Prognostic Scoring System for Myelodysplastic SyndromesNEJM Evidence, 2022
- Structural racism is a mediator of disparities in acute myeloid leukemia outcomesBlood, 2022
- Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high‐risk myelodysplastic syndromes: Challenges and opportunities in implementationCancer, 2021
- Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular TherapyTransplantation and Cellular Therapy, 2020
- Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR reportCancer, 2017
- Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple MyelomaTransplantation and Cellular Therapy, 2015
- Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient AgeTransplantation and Cellular Therapy, 2013
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Access to hematopoietic stem cell transplantationCancer, 2010